Latest Breaking News On - Clinical oncology gastrointestinal - Page 1 : comparemela.com

Latest Clinical Data of InnoCare s Gunagratinib Presented at 2023 ASCO GI

Latest Clinical Data of InnoCare s Gunagratinib Presented at 2023 ASCO GI
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongInnocare pharmaChunhua luShanghai east hospital of tongji universityCare pharmaClinical oncology gastrointestinalShanghai east hospitalTongji university

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sioux fallsSouth dakotaUnited statesAvera mckennan hospitalUniversity health centerSarah singletonShiong institute for medicineImmunitybio incDrug administrationExchange commissionCompany formAmerican society of clinical oncology gastrointestinalAmerican societyClinical oncology gastrointestinalSan francisco januaryPatrick soon shiong

AVEO Oncology Presents Three Posters for

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two.

United statesMichael baileyUniversity of florida health cancer centerPharma united kingdomDrug administrationEuropean unionPharmaceuticals incAmerican cancer societyClinical oncology gastrointestinalFlorida health cancer centerChief executive officerSafety data poster titleAdvanced hepatocellular carcinomaEfficacy resultsPreviously untreated patientsProgress poster presentation

Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test

Ashion Analytics to Present Data on the Value of Comprehensive Genomic Profiling of Gastrointestinal Cancers by Utilizing the GEM ExTra® Test News provided by Share this article Share this article PHOENIX, Jan. 15, 2021 /PRNewswire/ Ashion Analytics LLC, a CLIA-certified and CAP-accredited clinical laboratory announced today that they will present data at the 2021 American Society for Clinical Oncology Gastrointestinal (ASCO GI) virtual meeting. Abstract #109 Title: Genomic profiling of gastrointestinal cancers by comprehensive tumor-normal sequencing Authors: Fadel S. Alyaqoub, Pawan Noel, Szabolcs Szelinger, Thanemozhi G. Natarajan, Susan M. Dombrowski, Audrey A. Ozols, Laurie J. Goodman, Janine LoBello, Thomas Royce, Gargi D. Basu

United statesFadels alyaqoubSteve yozwiakSusanm dombrowskiAudreya ozolsPawan noelThanemozhig natarajanThomas royceSzabolcs szelingerJanine lobelloLauriej goodmanGargid basuTranslational genomics research institute tgenFashion analyticsAmerican society for clinical oncology gastrointestinalClinical oncology gastrointestinal

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021 The Company s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned

United statesUnited kingdomFrance generalRicky bhajunBrandon owensPorter novelliPierre louis germainNanobiotix immunoInternational organization for medical physicsNational cancer instituteCommunications departmentFrench financial markets authority autoritCompany nasdaqAmerican society of clinical oncology gastrointestinal symposiumExchange commission onInvestor relations department